Bromocriptine for diabetes mellitus type II

Cardiology in Review

Volumn 19, Issue 6, 2011, Pages 272-275

  Valiquette, Guy ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

bromocriptine; cardiovascular; complications; diabetes mellitus; hibernation

Indexed keywords

BROMOCRIPTINE MESILATE; DOPAMINE; GLUCOSE; HEMOGLOBIN A1C; LEPTIN; NORADRENALIN; PLACEBO; ROSIGLITAZONE;

ANGINA PECTORIS; CHEMOTHERAPY INDUCED EMESIS; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG SYNTHESIS; EXERCISE; FATIGUE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HIBERNATION; HUMAN; HYPOTENSION; INSULIN SENSITIVITY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION;

ANIMALS; BROMOCRIPTINE; DIABETES MELLITUS, TYPE 2; HIBERNATION; HUMANS; INSULIN RESISTANCE;

EID: 80054045839     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318229d2d2     Document Type: Review

References (35)

1. Available at: Http://www.drugs.com/mtm/parlodel.html. Accessed February 6, 2011.
2. Available at: Http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ DrugandBiologicApprovalReports/PriorityNDAandBLAApprovals/UCM090995.pdf. Accessed February 6, 2011.
3. Scranton R, Cincotta A. Bromocriptine-unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11:269-279.
4. Barnett AH, Chapman C, Gailer K, et al. Effects of bromocriptine on maturity onset diabetes. Postgrad Med J. 1980 56:11-14. (Pubitemid 10214677)
5. Toien O, Blake J, Edgar DM, et al. Hibernation in black bears: Independence of metabolic suppression from body temperature. Science. 2011;331:906-909.
6. Dausmann KH, Glos J, Ganzhorn JU, et al. Hibernation in a tropical primate. Nature. 2004 429:825-826. (Pubitemid 38843288)
7. Martin SL. Mammalian hibernation: A naturally reversible model for insulin resistance in man. Diabetes Vasc Dis Res. 2008;5:76-81. (Pubitemid 351839277)
8. Young RA. Fat, energy and mammalian survival. Am Zool. 1976;16:699-710.
9. Concannon P, Levac K, Rawson R, et al. Seasonal changes in serum leptin, food intake, and body weight in photoentrained woodchucks. Am J Physiol Regulatory Integrative Comp Physiol. 2001;281:R951-R959.
10. Zucker I. Pineal gland influences periods of circannual rhythms of ground squirrels. Am J Physiol Regulatory Integrative Comp Physiol. 1985;249: R111-R115. (Pubitemid 15243841)
11. Rothwell NJ, Stock MJ, Wyllie MG. Dopaminergic mechanisms in dietinduced thermogenesis and brown adipose tissue metabolism. Eur J Pharmacol. 1982;77:45-48. (Pubitemid 12209728)
12. Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters Mesocricetus auratus. Metabolism. 1995;44:1349-135.
13. Cincotta AH, MacEachrern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol. 1993;264:E285-E93.
14. Oltmans GA. Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob). Brain Res. 1983;369-373. (Pubitemid 13039723)
15. Cincotta AH, Tozzo E, Scislowski PW. Bromocriptine/SKF3839 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci. 1997;61:951-956. (Pubitemid 27348663)
16. Scislowski PW, Tozzo E, Zhang Y, et al. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes. 1999;23:425-431. (Pubitemid 29182403)
17. Lam CK, Chari M, Lam TK. CNS regulation of glucose homeostasis. Physiology. 2009;24:159-170.
18. Lee A, Ader M, Bray GA, et al. Diurnal variation in glucose tolerance: Cyclic suppression of insulin action and insulin secretion in normal-weight, but not obese, subjects. Diabetes. 1992;41:750-759.
19. Boden G, Chen X, Polansky M. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes. 1999;48:2182-2188. (Pubitemid 29521848)
20. Landgraf R, Landgraf-Leurs MM, Weissmann A, et al. Prolactin: A diabetogenic hormone. Diabetologia. 1977;13:99-104. (Pubitemid 8077629)
21. Barnett AH, Chapman G, Gailer K, et al. Effect of bromocriptine on maturity onset diabetes. Postgrad Med J. 1980;56:11-14. (Pubitemid 10214677)
22. Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: An insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002; 147: 77-84. (Pubitemid 34814743)
23. Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetic. Experientia. 1992;48:248-253.
24. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19:667-670. (Pubitemid 26182986)
25. Kamath V, Jones CN, Yip JC, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care. 1997;20:1697-1701. (Pubitemid 27463045)
26. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine-a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154-1161. (Pubitemid 30616805)
27. Nissen SE, Wolski K. Effects of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356: 2457-2471. (Pubitemid 46919772)
28. Nissen SE, Wolski K. Rosiglitazone revisited. Arch Int Med. 2010;170:1191-1201.
29. Guidance for Industry. Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071627.pdf. Accessed April 25, 2011.
30. Nissen SE. The rise and fall of rosiglitazone. Eur Heart J. 2010;31:773-776.
31. Weiss IA, Valiquette G, Schwarcz MD, et al. Heart disease and treatment of diabetes mellitus. In Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 3rd ed. Minneapolis, MN: Cardiotext; 2011: 413-424.
32. Scranton RE, Gaziano JM, Rutty D, et al. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord. 2007;7:3.
33. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33: 1503-1508.
34. Cycloset Prescribing Information. Available at: Www.accessdata.fda.gov/ drugsatfda-docs/label/2009/020866lbl.pdf. Accessed April 26, 2011.
35. Available at: Http://www.drugstore.com, Accessed May 3, 2011.